Ruxolitinib Therapy Appears Safe Prior to Allogeneic HSCT for Myelofibrosis

The results from a phase II prospective study of patients with primary or secondary myelofibrosis receiving ruxolitinib and then hematopoietic stem cell transplant could help define the optimal time between the two therapies to achieve the best outcome and avoid complications.